Association of Severe Insulin Resistance With Both Loss of Limb Fat and Elevated Serum Tumor Necrosis Factor Receptor Levels in HIV Lipodystrophy
- 1 December 2000
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 25 (4), 312-321
- https://doi.org/10.1097/00042560-200012010-00004
Abstract
HIV-lipodystrophy (HIV-LD) is characterized by the loss of body fat from the limbs and face, an increase in truncal fat, insulin resistance, and hyperlipidemia, factors placing affected patients at increased risk for vascular disease. This study evaluated insulin sensitivity and inflammatory status associated with HIV-LD and provides suggestions about its etiology. Insulin sensitivity and immune activation markers were assessed in 12 control subjects and 2 HIV-positive groups, 14 without and 15 with LD syndrome. Peripheral insulin sensitivity (mostly skeletal muscle) was determined with the hyperinsulinemic-euglycemic clamp. Circulating insulin-like growth factor (IGF) binding protein-1 (IGFBP-1) and free fatty acid (FFA) levels, and their response to insulin infusion were indicative of insulin responsiveness of liver and adipose tissue, respectively. Serum levels of soluble type 2 tumor necrosis factor-alpha (TNF-alpha) receptor (sTNFR2) were used as an indicator of immune activation. HIV-LD study subjects had significantly reduced (twofold) peripheral insulin sensitivity, but normal levels of FFA and reduced levels of IGFBP-1, relative to the nonlipodystrophy groups, indicating that the loss of insulin sensitivity was more pronounced in skeletal muscle than in liver or fat. The significant loss of peripheral fat in the HIV-LD group (34%; p <.05) closely correlated with the reduced peripheral insulin sensitivity (p =. 0001). Levels of sTNFR2 were elevated in all HIV-infected study subjects, but they were significantly higher in those with lipodystrophy than without, and sTNFR2 levels strongly correlated with the reduction in insulin sensitivity (p =.0001). Loss of peripheral fat, normal levels of FFA, and reduced levels of IGFBP-1 indicate that insulin resistance in HIV-LD is distinct from type 2 diabetes and obesity. The relationship between the degree of insulin resistance and sTNFR2 levels suggests an inflammatory stimulus is contributing to the development of HIV-associated lipodystrophy.Keywords
This publication has 43 references indexed in Scilit:
- Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Insulin Resistance in HIV Protease Inhibitor–Associated DiabetesJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- Endocrine and Metabolic Evaluation of Human Immunodeficiency Virus-Infected Patients with Evidence of Protease Inhibitor-Associated LipodystrophyJournal of Clinical Endocrinology & Metabolism, 1999
- Studies of Body Composition and Fat Distribution in HIV-Infected and Control SubjectsJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapyAIDS, 1999
- A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitorsAIDS, 1998
- Visceral abdominal-fat accumulation associated with use of indinavirThe Lancet, 1998
- “Buffalo hump” in men with HIV-1 infectionThe Lancet, 1998
- Metabolic Effects of Troglitazone Monotherapy in Type 2 Diabetes MellitusAnnals of Internal Medicine, 1998
- Pathophysiology of insulin resistance in human diseasePhysiological Reviews, 1995